GUANGZHOU, China --- Bio-Thera Solutions (688177:SH), a commercial-stagebiopharmaceutical company developing a pipeline of innovative therapies and biosimilars,today announced the company has reached an exclusivecommercialization and license agreement with IntasPharmaceuticals for BAT2506, a golimum...
DetailsGUANGZHOU, China and San José, Costa Rica- Bio-Thera Solutions, a commercial-stagebiopharmaceutical company developing innovative therapies and biosimilars, andSteinCares, one of Latin America’s leading specialty healthcare companies,announced today a new licensing agreement for two biosimilars u...
Guangzhou, China -- Bio-Thera Solutions (688177:SH), acommercial-stage biopharmaceutical company developing a pipeline of innovativetherapies and biosimilars, today announced that dosinghas begun in Phase IA/IIB clinical trial to study efficacy and safety of BAT6026 inpatients with moderate to sever...
GUANGZHOU, China --- Bio-Thera Solutions (688177:SH), acommercial-stage biopharmaceutical company developing a pipeline of innovativetherapies and biosimilars, today announced the company has reached a licensing agreement with Macter International Ltd. for BAT 17 06, its bevacizumab biosimilar, unde...
